In the study 1, patients showed lower occurrence of nausea, photophobia, and/or phonophobia at baseline, at 2 hours (Study 1) and at 4 hours (Studies 1, 2, and 3) using of Generic IMITREX Tablets compared to placebo.  

About 2 hours in advance in Studies 2 and 3 or 4 hours in Study 1, through 24 hours following the opening dose of study treatment, patients were given a second dose of study treatment or other medication for further treatment for pain relief.  

It has not been proved if doses above 50 mg do not provide a greater effect than 50 mg. it also has not been confirmed if treatment with Sumatriptan can lead to an increase in the severity of recurrent headaches. The efficacy of IMITREX Tablets did not show difference along with aura; gender, age, or weight of the patient; relationship to menses; duration of headache prior to treatment. The concomitant use of common migraine prophylactic drugs such as tricyclic antidepressants, beta-blockers, calcium channel blockers also showed no difference in the effectiveness of this drug. No satisfactory data are available to assess the impact of race on effectiveness.

The findings of these trials can not be supported because studies showed different results when made at different times with different patients. These studies were made by different researchers, using different criteria and/or different interpretations of the same criteria, under different conditions (dose, dosing regimen, etc.).  Japanese name of Sumatriptan is スマトリプタン